NKGen Biotech (NKGN) Competitors $0.17 +0.03 (+21.43%) As of 08/5/2025 02:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGN vs. LGVN, CYCC, ASBP, AYTU, RVPH, DARE, CLDI, CVKD, LSTA, and NAIIShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Longeveron (LGVN), Cyclacel Pharmaceuticals (CYCC), Aspire Biopharma (ASBP), Aytu BioPharma (AYTU), Reviva Pharmaceuticals (RVPH), Dare Bioscience (DARE), Calidi Biotherapeutics (CLDI), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Its Competitors Longeveron Cyclacel Pharmaceuticals Aspire Biopharma Aytu BioPharma Reviva Pharmaceuticals Dare Bioscience Calidi Biotherapeutics Cadrenal Therapeutics Lisata Therapeutics Natural Alternatives International NKGen Biotech (NYSE:NKGN) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Do analysts recommend NKGN or LGVN? Longeveron has a consensus price target of $8.67, suggesting a potential upside of 479.71%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do insiders & institutionals have more ownership in NKGN or LGVN? 76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 11.2% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, NKGN or LGVN? Longeveron has higher revenue and earnings than NKGen Biotech. Longeveron is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen BiotechN/AN/A-$82.94M-$2.45-0.07Longeveron$2.39M9.34-$15.97M-$6.28-0.24 Which has more volatility and risk, NKGN or LGVN? NKGen Biotech has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Does the media prefer NKGN or LGVN? In the previous week, Longeveron had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Longeveron and 2 mentions for NKGen Biotech. Longeveron's average media sentiment score of 0.33 beat NKGen Biotech's score of -0.50 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Longeveron 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is NKGN or LGVN more profitable? NKGen Biotech has a net margin of 0.00% compared to Longeveron's net margin of -760.72%. NKGen Biotech's return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Longeveron -760.72%-85.07%-70.74% SummaryLongeveron beats NKGen Biotech on 10 of the 16 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.64M$295.95M$5.56B$20.65BDividend YieldN/AN/A4.31%3.66%P/E Ratio-0.03N/A29.3729.27Price / SalesN/A448.74444.7462.32Price / CashN/A22.4435.8423.31Price / Book-0.0610.208.084.37Net Income-$82.94M-$111.61M$3.26B$996.36M7 Day Performance21.43%4.28%0.44%0.59%1 Month Performance-43.33%18.89%4.82%0.23%1 Year Performance-82.63%4.21%30.27%16.71% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen Biotech0.475 of 5 stars$0.17+21.4%N/A-82.5%$7.64MN/A-0.03N/AShort Interest ↑Gap UpLGVNLongeveron2.6866 of 5 stars$1.56-4.9%$8.67+455.6%-48.3%$24.48M$2.39M-0.2520Upcoming EarningsShort Interest ↑CYCCCyclacel Pharmaceuticals0.4155 of 5 stars$13.25-13.9%N/A-97.9%$24.39M$40K-0.0214Upcoming EarningsGap DownASBPAspire BiopharmaN/A$0.48-1.0%N/AN/A$23.82MN/A0.00N/AGap DownAYTUAytu BioPharma3.1995 of 5 stars$2.54-3.4%$10.00+293.7%-2.0%$23.61M$81M-3.53160RVPHReviva Pharmaceuticals2.8885 of 5 stars$0.47-4.1%$9.00+1,815.7%-50.0%$23.52MN/A-0.595Upcoming EarningsShort Interest ↑Gap UpDAREDare Bioscience1.3909 of 5 stars$2.48-2.7%$12.00+383.9%-29.8%$23.03M$10K-14.5930Upcoming EarningsCLDICalidi Biotherapeutics0.2641 of 5 stars$0.63+14.9%N/A-70.2%$22.94MN/A0.0038Short Interest ↑High Trading VolumeCVKDCadrenal Therapeutics2.303 of 5 stars$10.87-6.1%$32.00+194.4%N/A$22.77MN/A-1.174Gap UpLSTALisata Therapeutics2.3139 of 5 stars$2.57-2.3%$23.50+814.4%+0.7%$22.66M$1M-1.1230Positive NewsUpcoming EarningsNAIINatural Alternatives InternationalN/A$3.70+2.8%N/A-33.5%$22.24M$113.80M-2.66290Positive News Related Companies and Tools Related Companies Longeveron Alternatives Cyclacel Pharmaceuticals Alternatives Aspire Biopharma Alternatives Aytu BioPharma Alternatives Reviva Pharmaceuticals Alternatives Dare Bioscience Alternatives Calidi Biotherapeutics Alternatives Cadrenal Therapeutics Alternatives Lisata Therapeutics Alternatives Natural Alternatives International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKGN Stock Alerts